From Name:
From Email:
To Name:
To Email:

Optional Message:

Measuring the integration of stereotactic ablative radiotherapy plus surgery for early stage nonsmall cell lung cancer

from JAMA Oncology

Stereotactic ablative radiotherapy (SABR) is a standard treatment option in patients with medically inoperable early-stage nonsmall cell lung cancer (NSCLC), yet the pathologic complete response (pCR) rate after SABR is unknown. Neoadjuvant SABR in patients with cancer who are fit for resection has been hypothesized to improve local control and induce antitumor immune activity, potentially leading to better outcomes. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063